23 December 2016
I have some great news to share:
Recently, the work of my colleagues and collaborators was accepted and published in the prestigious journal European Urology. A retrospective analysis of the cohort presented in Scher et al. JAMA Oncology, this study investigated the scoring criteria of the AR-V7 biomarker in circulating tumor cells. We found that the AR-V7 is predictive of drug class-specific survival when the AR-V7 protein is localized to the nucleus of circulating tumor cells in metastatic prostate cancer patients: that patients who had these types of CTCs survived longer on taxane chemotherapy instead of androgen receptor signaling inhibitors like abiraterone, enzalutamide and apalutamide.
My individual contributions were lead biostatistician and drafting the manuscript. The open access article is available here: Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer